Veridex reigns in Immunicon
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics maker Immunicon lost its bid to end a 20-year exclusive marketing agreement with Johnson & Johnson/Veridex March 3, when the American Arbitration Association found that Veridex did not fault on its agreement to use its "best efforts" to market Immunicon's CellSearch circulating tumor cell assay, as Immunicon had alleged (1"The Gray Sheet" June 11, 2007, p. 10). Veridex also triumphed on its counterclaim that Immunicon was in "material breach" of the contract and was awarded $304,013. CellSearch is FDA-cleared to predict progression-free and overall survival in patients with metastatic breast, colorectal or prostate cancers
You may also be interested in...
Immunicon cuts staff 40%
Cell and molecular-based human diagnostic and life sciences research firm reduces its workforce by 45 employees, or 40% of its full-time equivalent platform development, R&D and marketing staff. The reduction in force comes after the firm recently lost its bid to end a 20-year exclusive marketing agreement with Johnson & Johnson/Veridex for its CellSearch cancer test, and reflects the potential impact of the arbitration decision on Immunicon's commercialization efforts, the firm says (1"The Gray Sheet" March 10, 2008, In Brief). The company expects to take a related charge of $1.3 million-$1.5 million in the first fiscal quarter of 2008
J&J-Immunicon Dispute Highlights Challenges Of Exclusive Agreements
A sales and marketing relationship gone sour between cancer diagnostic developer Immunicon and a Johnson & Johnson subsidiary illustrates the risks firms take when choosing an exclusive distributor
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.